Hausstaubmilbe Dermatophagoides Pteronyssinus Hal Allergy

Hausstaubmilbe Dermatophagoides Pteronyssinus Hal Allergy is a prescription allergen extract containing Dermatophagoides pteronyssinus (house dust mite) as the active ingredient. The product is supplied as a cutaneous extract, with strength not specified. It provides controlled skin exposure to assess or treat IgE‑mediated hypersensitivity to house dust mite allergens and is classified under ATC code V01AA02 for diagnostic skin testing and immunotherapy in the EU market.

Hausstaubmilbe Dermatophagoides Pteronyssinus Hal Allergy is employed in clinical practice for both diagnostic and therapeutic purposes related to house dust mite allergy.

- Diagnosis of IgE‑mediated allergic rhinitis caused by Dermatophagoides pteronyssinus. - Evaluation of allergic asthma triggered by house dust mite exposure. - Skin prick testing to confirm sensitization to Dermatophagoides pteronyssinus. - Component of allergen immunotherapy protocols aimed at inducing tolerance to house dust mite allergens. - Adjunct in research settings investigating dust‑mite–related allergic mechanisms. - Monitoring of treatment response during house dust mite immunotherapy. - Use in pediatric allergy clinics to assess early sensitization to dust mite allergens.

Local and systemic reactions may occur after cutaneous application of Hausstaubmilbe Dermatophagoides Pteronyssinus Hal Allergy; reported events vary in frequency and severity.

Common: - Mild erythema at the test site. - Small wheal or papule formation. - Transient itching or burning sensation. - Localized swelling lasting less than 24 hours. - Slight edema of surrounding skin. - Temporary flushing or warmth at the site. - Minor bruising at the injection site. - Temporary discoloration of the skin.

Serious: - Large wheal or extensive urticaria beyond the application area. - Systemic allergic reaction such as anaphylaxis. - Severe respiratory symptoms including bronchospasm. - Cardiovascular symptoms such as hypotension or tachycardia. - Neurological manifestations including dizziness or loss of consciousness.

Before using Hausstaubmilbe Dermatophagoides Pteronyssinus Hal Allergy, clinicians should evaluate patient history and follow specific safety measures to minimize risk.

- Confirm documented IgE‑mediated sensitization to Dermatophagoides pteronyssinus before testing or therapy. - Avoid use in patients with a history of severe anaphylactic reactions to dust‑mite extracts. - Perform the initial skin test in a setting equipped for emergency management. - Observe the patient for at least 30 minutes after application for early signs of systemic reaction. - Adjust or discontinue treatment in individuals who develop extensive local or systemic adverse effects. - Pregnant or lactating women should be assessed carefully, as safety data are limited. - Concomitant use of beta‑blockers may mask early signs of anaphylaxis.

Hausstaubmilbe Dermatophagoides Pteronyssinus Hal Allergy may interact with other medications or substances that influence immune or allergic responses.

Avoid: - Concurrent administration of other allergen extracts without medical supervision. - Use together with systemic immunosuppressants such as high‑dose corticosteroids during the initial phase. - Simultaneous use of biologic agents targeting IgE (e.g., omalizumab) without adjusting dosing schedule.

Use with caution: - Beta‑blockers, because they can interfere with treatment of anaphylaxis. - ACE inhibitors or angiotensin receptor blockers, which may exacerbate angioedema. - Antihistamines, which can mask local skin test reactions and affect interpretation. - NSAIDs, as they may increase the risk of bronchospasm in sensitive individuals.